<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://harvardscience.harvard.edu" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>all Adolfo Ferrando stories</title>
 <link>http://harvardscience.harvard.edu/stories/person/1521</link>
 <description>Stories and external links referencing a person (RSS)</description>
 <language>en</language>
<item>
 <title>Gene signature identifies leukemia patients who should avoid transplants</title>
 <link>http://harvardscience.harvard.edu/medicine-health/articles/gene-signature-identifies-leukemia-patients-who-should-avoid-transplants</link>
 <description>&lt;!--paging_filter--&gt;&lt;p&gt;It was previously known that only slightly over half of the patients with adult T-cell acute lymphoblastic leukemia (ALL) could be cured with chemotherapy. Adult ALL patients often undergo transplants in an effort to beat back the stubborn disease. Until now there was no way to identify those who have a more favorable outlook and shouldn&#039;t undergo risky bone marrow transplantation. Now an international team of researchers led by scientists at Dana-Farber Cancer Institute in Boston have used a gene test to identify certain patients with ALL who can be successfully treated with chemotherapy alone and should not be subjected to the rigors of bone marrow transplants. Adolfo Ferrando and A.&lt;/p&gt;
&lt;p&gt;&lt;a href=&quot;http://harvardscience.harvard.edu/medicine-health/articles/gene-signature-identifies-leukemia-patients-who-should-avoid-transplants&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <pubDate>Mon, 26 Mar 2007 05:28:43 -0400</pubDate>
 <dc:creator>70652986</dc:creator>
 <guid isPermaLink="false">3350 at http://harvardscience.harvard.edu</guid>
</item>
</channel>
</rss>
